Dr James Flanagan, completed his PhD in 2002 at the Queensland Institute of Medical Research in Brisbane, Australia, and has pursued postdoctoral work in Cancer Genetics, Epigenetics and Cancer Epigenetics. He was awarded a Breast Cancer Campaign Scientific Fellowship (Imperial, 2009-2014) and Senior Lecturer (2014-2019) and is now Reader in Epigenetics (2019-present) in the Division of Cancer, Dept. of Surgery and Cancer, Faculty of Medicine at Imperial College London. He was awarded the British Association of Cancer Research Translational Researcher Award in 2011 and is the principal investigator (PI) for the OCA funded programme "Risk and Prevention" based in the Ovarian Cancer Action Research Centre and PI of the CRUK funded project "Cancer Loyalty Card Study (CLOCS)"
In 2021 he was appointed as the Director of the MRes Cancer Biology
et al., 2017, Platinum-based chemotherapy induces methylation changes in blood DNA associated with overall survival in ovarian cancer patients, Clinical Cancer Research, Vol:23, ISSN:1557-3265, Pages:2213-2222
et al., 2015, Epigenome-wide association study reveals decreased average methylation levels years before breast cancer diagnosis, Clinical Epigenetics, Vol:7, ISSN:1868-7083
et al., 2013, Epigenome-wide association study in the European Prospective Investigation into Cancer and Nutrition (EPIC-Turin) identifies novel genetic loci associated with smoking, Human Molecular Genetics, Vol:22, ISSN:0964-6906, Pages:843-851
et al., 2012, Intragenic ATM Methylation in Peripheral Blood DNA as a Biomarker of Breast Cancer Risk, Cancer Research, Vol:72, ISSN:0008-5472, Pages:2304-2313
et al., 2010, DNA Methylome of Familial Breast Cancer Identifies Distinct Profiles Defined by Mutation Status, American Journal of Human Genetics, Vol:86, ISSN:0002-9297, Pages:420-433